Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2020-2026
SKU ID : QYR-15124254 | Publishing Date : 24-Jan-2020 | No. of pages : 93
Detailed TOC of Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2020-2026
Table of Contents1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Afinitor (Everolimus)
1.4.3 Avastin (Bevacizumab)
1.4.4 Cabomety (Cabozantinib)
1.4.5 Inlyta (Axitinib)
1.4.6 Nexavar (Sorafenib)
1.4.7 Proleukin (Aldesleukin)
1.4.8 Torisel (Temsirolimus)
1.4.9 Sutent (Sunitinib)
1.4.10 Votrient (Pazopanib)
1.5 Market by Application
1.5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Perspective (2015-2026)
2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Growth Trends by Regions
2.2.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Market Size
3.1.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue (2015-2020)
3.1.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio
3.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2019
3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players Head office and Area Served
3.4 Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
3.5 Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Type (2015-2020)
4.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2021-2026)
5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Application (2015-2026)
5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)
5.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
6.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in North America (2019-2020)
6.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
6.4 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
7.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Europe (2019-2020)
7.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
7.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)
8 China
8.1 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
8.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in China (2019-2020)
8.3 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
8.4 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
9.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Japan (2019-2020)
9.3 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
9.4 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
10.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)
11 India
11.1 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
11.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in India (2019-2020)
11.3 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
11.4 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020)
12.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020)
12.4 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020)
13Key Players Profiles
13.1 Active Biotech Ab
13.1.1 Active Biotech Ab Company Details
13.1.2 Active Biotech Ab Business Overview and Its Total Revenue
13.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
13.1.4 Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020))
13.1.5 Active Biotech Ab Recent Development
13.2 Amgen
13.2.1 Amgen Company Details
13.2.2 Amgen Business Overview and Its Total Revenue
13.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
13.2.4 Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
13.2.5 Amgen Recent Development
13.3 Bayer AG
13.3.1 Bayer AG Company Details
13.3.2 Bayer AG Business Overview and Its Total Revenue
13.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
13.3.4 Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
13.3.5 Bayer AG Recent Development
13.4 Cipla Limited
13.4.1 Cipla Limited Company Details
13.4.2 Cipla Limited Business Overview and Its Total Revenue
13.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
13.4.4 Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
13.4.5 Cipla Limited Recent Development
13.5 Roche Holding AG
13.5.1 Roche Holding AG Company Details
13.5.2 Roche Holding AG Business Overview and Its Total Revenue
13.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
13.5.4 Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
13.5.5 Roche Holding AG Recent Development
13.6 Glaxosmithkline Plc
13.6.1 Glaxosmithkline Plc Company Details
13.6.2 Glaxosmithkline Plc Business Overview and Its Total Revenue
13.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
13.6.4 Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
13.6.5 Glaxosmithkline Plc Recent Development
13.7 Novartis Ag
13.7.1 Novartis Ag Company Details
13.7.2 Novartis Ag Business Overview and Its Total Revenue
13.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
13.7.4 Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
13.7.5 Novartis Ag Recent Development
13.8 Pfizer, Inc.
13.8.1 Pfizer, Inc. Company Details
13.8.2 Pfizer, Inc. Business Overview and Its Total Revenue
13.8.3 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
13.8.4 Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
13.8.5 Pfizer, Inc. Recent Development
14Analyst's Viewpoints/Conclusions
15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Figures, Tables and Charts Available in Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2020-2026
List of TablesTable 1. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue
Table 3. Ranking of Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Afinitor (Everolimus)
Table 6. Key Players of Avastin (Bevacizumab)
Table 7. Key Players of Cabomety (Cabozantinib)
Table 8. Key Players of Inlyta (Axitinib)
Table 9. Key Players of Nexavar (Sorafenib)
Table 10. Key Players of Proleukin (Aldesleukin)
Table 11. Key Players of Torisel (Temsirolimus)
Table 12. Key Players of Sutent (Sunitinib)
Table 13. Key Players of Votrient (Pazopanib)
Table 14. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2015-2020)
Table 18. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Strategy
Table 24. Main Points Interviewed from Key Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players
Table 25. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Players (2015-2020) (Million US$)
Table 26. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players (2015-2020)
Table 27. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2019)
Table 28. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
Table 31. Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 34. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Share by Type (2015-2020)
Table 35. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2021-2026)
Table 36. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Share by Application (2015-2020)
Table 37. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 38. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Share by Application (2021-2026)
Table 39. North America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 41. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 42. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 43. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 44. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 45. Europe Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 47. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 49. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 51. China Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 52. China Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 53. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 54. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 55. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 56. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 57. Japan Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 59. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 61. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 65. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 67. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 69. India Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 70. India Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 71. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 72. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 73. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 74. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020)
Table 77. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020)
Table 79. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020)
Table 81. Active Biotech Ab Company Details
Table 82. Active Biotech Ab Business Overview
Table 83. Active Biotech Ab Product
Table 84. Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 85. Active Biotech Ab Recent Development
Table 86. Amgen Company Details
Table 87. Amgen Business Overview
Table 88. Amgen Product
Table 89. Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 90. Amgen Recent Development
Table 91. Bayer AG Company Details
Table 92. Bayer AG Business Overview
Table 93. Bayer AG Product
Table 94. Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 95. Bayer AG Recent Development
Table 96. Cipla Limited Company Details
Table 97. Cipla Limited Business Overview
Table 98. Cipla Limited Product
Table 99. Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 100. Cipla Limited Recent Development
Table 101. Roche Holding AG Company Details
Table 102. Roche Holding AG Business Overview
Table 103. Roche Holding AG Product
Table 104. Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 105. Roche Holding AG Recent Development
Table 106. Glaxosmithkline Plc Company Details
Table 107. Glaxosmithkline Plc Business Overview
Table 108. Glaxosmithkline Plc Product
Table 109. Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 110. Glaxosmithkline Plc Recent Development
Table 111. Novartis Ag Company Details
Table 112. Novartis Ag Business Overview
Table 113. Novartis Ag Product
Table 114. Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 115. Novartis Ag Recent Development
Table 116. Pfizer, Inc. Business Overview
Table 117. Pfizer, Inc. Product
Table 118. Pfizer, Inc. Company Details
Table 119. Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$)
Table 120. Pfizer, Inc. Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type: 2020 VS 2026
Figure 2. Afinitor (Everolimus) Features
Figure 3. Avastin (Bevacizumab) Features
Figure 4. Cabomety (Cabozantinib) Features
Figure 5. Inlyta (Axitinib) Features
Figure 6. Nexavar (Sorafenib) Features
Figure 7. Proleukin (Aldesleukin) Features
Figure 8. Torisel (Temsirolimus) Features
Figure 9. Sutent (Sunitinib) Features
Figure 10. Votrient (Pazopanib) Features
Figure 11. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2020 VS 2026
Figure 12. Hospitals Case Studies
Figure 13. Clinic Case Studies
Figure 14. Others Case Studies
Figure 15. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Report Years Considered
Figure 16. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 17. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions: 2020 VS 2026
Figure 18. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2021-2026)
Figure 19. Porter's Five Forces Analysis
Figure 20. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players in 2019
Figure 21. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2019
Figure 22. The Top 10 and 5 Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2019
Figure 23. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Active Biotech Ab Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Active Biotech Ab Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 32. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Amgen Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 34. Bayer AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Bayer AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 36. Cipla Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Cipla Limited Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 38. Roche Holding AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Roche Holding AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 40. Glaxosmithkline Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Glaxosmithkline Plc Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 42. Novartis Ag Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Novartis Ag Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 44. Pfizer, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Pfizer, Inc. Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)
Figure 46. Bottom-up and Top-down Approaches for This Report
Figure 47. Data Triangulation
Figure 48. Key Executives Interviewed
Keyplayers in Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2020-2026
Active Biotech AbAmgen
Bayer AG
Cipla Limited
Roche Holding AG
Glaxosmithkline Plc
Novartis Ag
Pfizer, Inc.